Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BIO | Bio-Rad A Common Stock | Options Exercise | $598K | +2K | +156.02% | $299.24 | 3.28K | Sep 1, 2021 | Direct | F1 |
transaction | BIO | Bio-Rad A Common Stock | Sale | -$609K | -750 | -22.85% | $812.27 | 2.53K | Sep 1, 2021 | Direct | F2 |
transaction | BIO | Bio-Rad A Common Stock | Sale | -$529K | -651 | -25.71% | $813.15 | 1.88K | Sep 1, 2021 | Direct | F3 |
transaction | BIO | Bio-Rad A Common Stock | Sale | -$488K | -599 | -31.85% | $814.09 | 1.28K | Sep 1, 2021 | Direct | F4 |
transaction | BIO | Bio-Rad A Common Stock | Options Exercise | $0 | +902 | +70.36% | $0.00 | 2.18K | Sep 2, 2021 | Direct | F5 |
transaction | BIO | Bio-Rad A Common Stock | Tax liability | -$370K | -448 | -20.51% | $825.77 | 1.74K | Sep 2, 2021 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | BIO | Restricted Stock Units | Award | $0 | +2.53K | $0.00 | 2.53K | Sep 1, 2021 | Bio-Rad A Common Stock | 2.53K | $0.00 | Direct | F6, F7 | |
transaction | BIO | Non-Qualified Stock Option (right to buy) | Award | $0 | +2.53K | $0.00 | 2.53K | Sep 1, 2021 | Bio-Rad A Common Stock | 2.53K | $814.95 | Direct | F8 | |
transaction | BIO | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -2K | -40% | $0.00 | 3K | Sep 1, 2021 | Bio-Rad A Common Stock | 2K | $299.24 | Direct | F9 |
transaction | BIO | Restricted Stock Units | Options Exercise | $0 | -902 | -24.99% | $0.00 | 2.71K | Sep 2, 2021 | Bio-Rad A Common Stock | 902 | $0.00 | Direct | F6, F10 |
Id | Content |
---|---|
F1 | Includes 13.9278 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2021. |
F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.70 to $812.69, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.71 to $813.34, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.02 to $814.11, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
F5 | Shares of Class A common stock acquired on the vesting of restricted stock units. |
F6 | Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. |
F7 | The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
F8 | The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. |
F9 | The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2020, which was the first anniversary of the date on which the option was granted. |
F10 | On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |